OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Next-generation therapies for pancreatic cancer
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Conor Buckley, Eileen M. O’Reilly
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 1-3, pp. 55-72
Open Access | Times Cited: 12
Showing 12 citing articles:
Natural Compounds for Preventing Age-Related Diseases and Cancers
Mi‐Ran Ki, Sol Youn, Dong Hyun Kim, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7530-7530
Open Access | Times Cited: 7
Mi‐Ran Ki, Sol Youn, Dong Hyun Kim, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7530-7530
Open Access | Times Cited: 7
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Umar Hayat, Phillip Croce, Aseel Saadeh, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1129-1129
Open Access
Umar Hayat, Phillip Croce, Aseel Saadeh, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1129-1129
Open Access
PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy
Kazuya Matsumoto, Yoshinori Matsumoto, Jun Wada
Frontiers in Immunology (2025) Vol. 16
Open Access
Kazuya Matsumoto, Yoshinori Matsumoto, Jun Wada
Frontiers in Immunology (2025) Vol. 16
Open Access
Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state
Cassandra Catacalos-Goad, Joseph A. Hawkins, Quinton Krueger, et al.
Journal of Virology (2025)
Open Access
Cassandra Catacalos-Goad, Joseph A. Hawkins, Quinton Krueger, et al.
Journal of Virology (2025)
Open Access
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
Bingyu Li, Qiong Zhang, Claire Castaneda, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2175-2175
Open Access | Times Cited: 2
Bingyu Li, Qiong Zhang, Claire Castaneda, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2175-2175
Open Access | Times Cited: 2
EUS-guided radiofrequency ablation in pancreatic cancer: Promising but still questionable!
Joan B. Gornals
Gastrointestinal Endoscopy (2024) Vol. 100, Iss. 2, pp. 259-261
Closed Access | Times Cited: 1
Joan B. Gornals
Gastrointestinal Endoscopy (2024) Vol. 100, Iss. 2, pp. 259-261
Closed Access | Times Cited: 1
Development and external validation of a prognostic nomogram to predict survival in patients aged ≥60 years with pancreatic ductal adenocarcinoma
Zheng Binjiao, Gangfeng Ding, Guangrong Lu, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 6, pp. 2751-2766
Open Access | Times Cited: 1
Zheng Binjiao, Gangfeng Ding, Guangrong Lu, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 6, pp. 2751-2766
Open Access | Times Cited: 1
Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system
Ruiqi Zhao, Mengyao Han, Sen Lin, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1295-1307
Closed Access | Times Cited: 1
Ruiqi Zhao, Mengyao Han, Sen Lin, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 10, pp. 1295-1307
Closed Access | Times Cited: 1
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence
Fatemeh Moosavi, Bahareh Hassani, Somayeh Nazari, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189185-189185
Closed Access | Times Cited: 1
Fatemeh Moosavi, Bahareh Hassani, Somayeh Nazari, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189185-189185
Closed Access | Times Cited: 1
NORPACT-1: implications for future trials – Authors' reply
Knut Jørgen Labori, Svein Olav Bratlie, Svein Dueland, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 408-409
Closed Access
Knut Jørgen Labori, Svein Olav Bratlie, Svein Dueland, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 5, pp. 408-409
Closed Access
Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer – real world data from the NORPACT-2 study
Ingvild Farnes, Marius Lund‐Iversen, Lars Aabakken, et al.
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 1093-1096
Open Access
Ingvild Farnes, Marius Lund‐Iversen, Lars Aabakken, et al.
Scandinavian Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 1093-1096
Open Access
Efficacy of Gemcitabine Plus Nab-paclitaxel in Second-line Treatment of Metastatic Pancreatic Cancer: a Multicenter Retrospective Study in Turkey
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Research Square (Research Square) (2024)
Closed Access
Yasin Sezgin, Oğur Karhan, Mehmet Naci Aldemir, et al.
Research Square (Research Square) (2024)
Closed Access
